Trial Profile
Multicenter phase II study of FOLFIRI and bevacizumab as second-line treatment in advanced or recurrent colorectal cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PROMETEUS-II
- Sponsors Yakult Honsha
- 02 Apr 2009 New trial record.